Last reviewed · How we verify
PB-201
PB-201 is a PEGylated biologic therapeutic designed to modulate immune function or target a specific disease pathway.
At a glance
| Generic name | PB-201 |
|---|---|
| Sponsor | PegBio Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a product from PegBio Co., Ltd., PB-201 likely leverages PEGylation technology to improve pharmacokinetic properties of a biologic molecule. The specific mechanism depends on its molecular target, which is not publicly disclosed in available sources. Further clinical data from Phase 3 trials would clarify its precise mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy (PHASE3)
- Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus (PHASE3)
- Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |